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Abstract
Background:  Recombinant antibodies are essential reagents for research, diagnostics and
therapy. The well established production host Escherichia coli relies on the secretion into the
periplasmic space for antibody synthesis. Due to the outer membrane of Gram-negative bacteria,
only a fraction of this material reaches the medium. Recently, the Gram-positive bacterium Bacillus
megaterium was shown to efficiently secrete recombinant proteins into the growth medium. Here
we evaluated B. megaterium for the recombinant production of antibody fragments.
Results: The lysozyme specific single chain Fv (scFv) fragment D1.3 was succesfully produced using
B. megaterium. The impact of culture medium composition, gene expression time and culture
temperatures on the production of functional scFv protein was systematically analyzed. A
production and secretion at 41°C for 24 h using TB medium was optimal for this individual scFv.
Interestingly, these parameters were very different to the optimal conditions for the expression of
other proteins in B. megaterium. Per L culture supernatant, more than 400 μg of recombinant His6-
tagged antibody fragment were purified by one step affinity chromatography. The material
produced by B. megaterium showed an increased specific activity compared to material produced
in E. coli.
Conclusion: High yields of functional scFv antibody fragments can be produced and secreted into
the culture medium by B. megaterium, making this production system a reasonable alternative to E.
coli.
Background
Recombinant antibodies and antibody fragments are
important tools for research, diagnostics [1] and therapy
[2]. Further, the generation of monoclonal antibodies for
proteome research, ideally against each human protein, is
a massive challenge [3]. Here, phage display has evolved
into a valuable method for the selection of antibody frag-
ments for this purpose [4]. Recombinant antibody frag-
ments can be selected from huge antibody gene libraries
against any target by an in vitro panning procedure [5,6].
Furthermore, the panning procedure can be integrated
into high throughput technologies [7]. For the production
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of large numbers of selected antibodies the established
systems like mammalian cell culture [8], Pichia pastoris [9]
or plants [10] are expensive, complicated and time con-
suming. The recombinant production of antibody frag-
ments requires the folding and association of at least two
different domains (VH and VL) and includes the forma-
tion of disulphide bonds. This results in lower yields com-
pared to single domain enzymes. Overall, the production
rate is strongly dependent on the individual sequence of
the antibody. However, using appropriate bacterial signal
peptides, antigen binding Fv fragments consisting of the
VH and VL domain of an antibody have been produced in
E. coli [11]. Improved yields of functional material were
achieved by the linking of VH and VL by a 15 – 25 amino
acid linker, resulting in the production of a single
polypeptide, the scFv (single chain fragment variable)
[12,13]. However, Gram-negative bacteria like E. coli
secrete proteins mostly into the periplasm [14]. Only in
rare cases can the scFv be isolated in higher amounts from
the supernatant [15]. The use of a Gram-positive bacte-
rium could facilitate the scFv production due to the lack
of an outer membrane allowing direct secretion of pro-
teins into the growth medium. The Gram-positive bacteria
Bacillus brevis [16,17] and Bacillus subtilis [18,19] have
already been succesfully used for the production of anti-
body fragments. In contrast to B. subtilis, B. megaterium
does not produce alkaline proteases. Another advantage
of this bacterium is the high stability of plasmids during
growth [20], which allows a stable gene expression in long
term cultivations and bioreactors. B. megaterium has been
used for the production of several recombinant proteins,
e.g. dextransucrase [21], glucanase [22] and Clostridium
difficile toxin A [23]. Recently, a set of free replication vec-
tors and genetically optimized B. megaterium strains for
the intra- and extracellular production of affinity tagged
recombinant proteins were developed. They were succes-
fully employed for the production and purification of dex-
transucrase [21], levansucrase [24,25], penicillin amidase
[26] and a hydrolase [27].
Methods for large scale high cell density bioreactor culti-
vation were established [28,29]. Here, we evaluate B. meg-
aterium  for its capability to produce and secrete
recombinant antibody fragments.
Results
Construction of the pEJBmD1.3scFv vector
The vector pEJBmD1.3scFv for the production and the
export of the lysozyme specific single chain Fv (scFv) anti-
body fragment was constructed from the B. megaterium
expression vector pHIS1525 [25]. To obtain pEJBmop-
SplipA codon usage optimized DNA encoding the signal
peptide splipA of B. megaterium lipase A was integrated and
a residual E. coli tetracycline gene fragment was removed
from the vector. The scFv gene fragment encoding the
murine anti-hen egg white lysozyme antibody D1.3
[30,31] was amplified by polymerase chain reaction
(PCR) from the vector pHAL1-D1.3scFv, a pHAL1-D1.3
variant [32], and cloned into pEJBmopSplipA, resulting in
the vector pEJBMD1.3scFv. The structure of the vector
pEJBmD1.3scFv is given in figure 1. Efficient cloning of
gene fragments encoding antibody fragments in E. coli
DH10B was sustained by the cotransformation of
pMMEc4 encoding the xylose repressor gene xylR under
control of an arabinose promoter. Continuous xylR
expression led to the succesful repression of the otherwise
leaky B. megaterium xylA promoter in E. coli. After transfor-
mation of B. megaterium with this vector and the induc-
tion of gene expression with xylose, antigen binding by
culture supernatant was confirmed by lysozyme ELISA
(experimental setup as shown in Fig. 2) (data not shown).
However, the initial yields were low and required signifi-
cant optimization.
Production temperature
The impact of the temperature on the xylose induced pro-
duction of scFv in B. megaterium was evaluated first. Eight
different temperatures from 23°C to 45°C were analyzed
using LB medium for cultivation and a gene expresion
time of 24 h. The yields of functional scFv were estimated
by antigen enzyme-linked immunosorbent assay (ELISA)
on lysozyme. The best yield of functional D1.3 fragments
was obtained at a cultivation temperature of 41°C (Fig.
2). Interestingly, in contrast to E. coli secretion systems,
yields did not drop significantly at even higher tempera-
tures than 37°C.
Optimal medium
D1.3 scFv production at 41°C for 18 h was induced in
minimal media M9 or A5, LB medium and the rich media
2xTY and TB, respectively. The secreted scFv protein was
analyzed for antigen binding function by antigen ELISA
(Fig. 3A) and for its molecular mass and potential degra-
dation by SDS polyacrylamid gel electrophoresis (SDS-
PAGE) and immunobloting (Fig. 3B). The minimal media
did not allow production of functional scFv. The use of LB
medium resulted in a low production of functional scFvs.
Significant production of funtional scFvs was observed
using the rich medium 2xTY. The highest production was
achieved by using TB medium which is the richest of the
used media. Here, the immunoblot indicated some degra-
dation products.
Expression time
The optimal expression time for scFvs in B. megaterium
was determined at 41°C using TB medium for activation.
Samples were taken from the supernatant between 0 and
48 h after induction of the recombinant gene expression
with xylose and analyzed by antigen ELISA (Fig. 4A) and
immunoblot (Fig. 4B). Functional scFv fragments wereMicrobial Cell Factories 2007, 6:2 http://www.microbialcellfactories.com/content/6/1/2
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Construction of plasmid pEJBmD1.3scFv for the production of scFv antibody fragment D1.3 in B. megaterium Figure 1
Construction of plasmid pEJBmD1.3scFv for the production of scFv antibody fragment D1.3 in B. megaterium. The complete 
scFv ORF plus the complete promoter region were verified by nucleotide sequencing. Abbreviations: bla: β-lactamase gene for 
ampicillin resistence; colE1: E. coli origin of plasmid replication; F1 IR: intergenic region of phage f1; gIII: fd phage gene III; His-tag: 
synthetic tag binding to 6xhistidine; ori: B. megaterium origin of plasmid replication; PlacZ: promoter of the bacterial lac operon; 
PxylA: xylose inducible promoter; RBS: ribosome binding site; repU: a gene essential for plasmid replication in B. megaterium; 
scFv: single chain fragment variable; SPlipA: signal peptide sequence of B. megaterium extracellular esterase LipA; SPpelB: signal 
peptide sequence of bacterial pectate lyase; strep-tag II: synthetic tag binding to streptactin; terminator: sequence terminating 
transcription; tet: tetracyclin resistence gene; VH: sequence encoding the variable fragment of the heavy chain; VL: sequence 
encoding the variable fragment of the light chain chain; xylR: xylose repressorMicrobial Cell Factories 2007, 6:2 http://www.microbialcellfactories.com/content/6/1/2
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detectable 6 h after induction. The amount of secreted
scFv protein continuously increased until 24 hours after
induction. A longer cultivation time resulted in a slight
reduction of functional scFv with the total amount of anti-
body fragments still increasing. From 12 h on, degrada-
tion products of the antibody fragment were detected.
Comparison of B. megaterium and E. coli
The anti-lysozyme D1.3 scFv was purified from culture
supernatant of B. megaterium or  E. coli periplasm and
supernatant. The material was purified by immobilized
metal affinity chromatography (IMAC). A yield of 410 μg/
L scFv after purification was obtained from B. megaterium,
whereas 290 μg/L were obtained from E. coli.
Serial dilutions of the purified scFv D1.3 produced by
either E. coli or B. megaterium were analyzed by antigen
ELISA on lysozyme (Fig. 5). The scFvs produced in B. meg-
aterium showed higher specific antigen binding compared
to the scFvs produced in E. coli, when same amounts of
antibody fragments were applied to ELISA.
Both the higher concentration and the better specific
activity indicate an improved enrichment from B. megate-
rium culture supernatant by a single IMAC purification
step, when compared to E. coli material.
Discussion
For many applications of antibodies, full length IgG mate-
rial is not mandatory. For example, for research and diag-
Impact of the cultivation temperature on the scFv production Figure 2
Impact of the cultivation temperature on the scFv production. Production of functional antibodies was analyzed by antigen 
binding ELISA of D1.3 scFvs of 50 μL culture supernatant after 24 h production in 100 mL scale. Mean values and standard devi-
ations of data obtained from three different cultures are given. Antigens: 1 μg/well lysozyme or 1 μg/well control protein BSA. 
The D1.3 antibodies were detected using mAb mouse anti-His and goat anti-mouse IgGHRP (Fab specific).Microbial Cell Factories 2007, 6:2 http://www.microbialcellfactories.com/content/6/1/2
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Impact of different culture media on the production of functional scFvs Figure 3
Impact of different culture media on the production of functional scFvs. A Antigen binding ELISA with 50 μL culture superna-
tant from 18 h production in 100 mL scale, performed as described in figure 2. Mean values and standard deviations of data 
obtained from three different cultures are given. B Immunoblot of culture supernatant. Ammonium sulfate precipated scFvs 
from 1.5 mL supernatant were separated by reducing SDS-PAGE (12 %) and detected using mAb mouse anti-His and goat anti-
mouse IgG AP (Fab specific).
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Impact of the production time on the yield of functional scFvs (TB medium, 41°C) Figure 4
Impact of the production time on the yield of functional scFvs (TB medium, 41°C). A Antigen binding ELISA with 50 μL culture 
supernatant from different time points, performed as described in figure 2 and 3. Mean values and standard deviations of data 
obtained from three different cultures are given. B Immunoblot of produced scFvs. Ammonium sulphate precipated scFvs from 
1 mL supernatant were separated by reducing SDS-PAGE (12 %) and detected as described in figure 3.
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nostics, correctly glycosylated IgG produced in
mammalian cell lines are not necessary. Antigen binding
antibody fragments, like Fab or scFv, are sufficient for
many immunological standard assays e.g. immunoblot,
ELISA, immunohistochemistry or immunoprecipitation.
In contrast to full IgG molecules, these antigen binding
fragments can conveniently be produced in E. coli.
Although this production system is widely used, corre-
sponding yields are somehow limited and in particular
hampered by the inefficient secretion, leaving more than
90 % of the produced scFv e inside of the cell. Moreover,
the majority of protein is found denatured in form of
insoluble inclusion bodies [33]. These observations stim-
ultated the search for alternative production systems.
Novel production systems could enhance the yield of
functional antibody fragments or allow cheaper and easier
production and purification. Various microorganism
beside E. coli, like B. subtilis [18,19], B. brevis [16,17], Pro-
teus mirabilis [34] or Lactobacillus zeae [35] have been used
for the production of recombinant antibody fragments.
Among these, Gram-positive bacteria in particular offer
the opportunity to avoid the periplasm preparation step
by secreting directly into the medium. In this study, the
parameters for the scFv production in B. megaterium were
established using the anti-lysozyme scFv D1.3 [30,31], an
antibody fragment that has already been widely used to
evaluate selection a production methods. Remarkably, the
optimal yields of functional scFv fragments were obtained
Antigen ELISA of purified D1.3 scFv from E. coli or Bacillus megaterium Figure 5
Antigen ELISA of purified D1.3 scFv from E. coli or Bacillus megaterium. Antigen: 1 μg/well lysozyme. The detection was per-
formed as described in figure 2-4.Microbial Cell Factories 2007, 6:2 http://www.microbialcellfactories.com/content/6/1/2
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at 41°C, 24 h production time and in TB medium. These
conditions differ significantly from those established for
the production of this protein class in E. coli, Bacillus sub-
tilis or Bacillus brevis. When using E. coli, a broad tempera-
ture range using 22°C, 25°C, 30°C or 37°C was
successfully used for the expression of different antibody
fragments with a slight advantage of lower temperatures
[31,32,36-40]. For B. subtilis 37°C, 6 – 8 h expression time
and rich medium was used for the expression of scFvs
[19], wheras for Bacillus brevis 30°C, 3 days and THB
medium was preferable [17]. For the production of other
recombinant proteins in B. megaterium, like dextransu-
crase, 37°C was found to be optimal [21]. As it is known
that folding is usually the limiting step in antibody pro-
duction in various organisms [37,41,42], a possible heat
shock effect, leading to improved chaperone expression,
may explain these differences.
The production of the D1.3 scFv in B. megaterium led to a
higher yield of functional antibody fragments compared
to our standard E. coli production system, whereas a frac-
tion of degraded scFvs were detected in the B. megaterium
production. The production of this particular scFv can
yield up to of 0.8 – 1 mg/L using a different E. coli expres-
sion system after extensive optimization [43]. The B. meg-
aterium  production strains have not been optimized
compared to the long lasting optimization of E. coli and
other Bacillus strains. When using E. coli, a yield of 1 – 2 g/
L were obtained when producing a human breast tumor
marker protein p185HER2 specific Fab fragment [44].
When using Bacillus strains, e.g. using B. subtilis 10 – 15
mg/L of a fibrin specific scFv were produced [19] or when
using B. brevis Fab fragments were produced at a level of
100 mg/L [16]. Furthermore, the yield is strongly depend
on the individual sequence of the produced antibody frag-
ment.
This study showed, that after a single purification step
using a recombinant His6-tag, both the concentration of
the obtained material and its functional activity are supe-
rior to E. coli scFv prepared in parallel.
Conclusion
B. megaterium allows the production of functional scFv
fragments by secretion into the culture medium. The spe-
cific activity of material obtained from B. megaterium was
higher than that obtained from E. coli. Therefore, B. mega-
terium can be added to the list of microbial production
hosts able to handle the demanding folding and secretion
of antibody fragments. The B. megaterium production sys-
tem offers a serious alternative to E. coli for the production
of recombinant antibody fragments, in particular for
research and diagnostic purposes.
Methods
Vector construction
Standard cloning procedures were performed according to
Sambrook and Russell [45]. The pEJBmD1.3scFv vector
was derived from the B. megaterium expression vector
pHIS1525 [25]. The vector pHIS1525 was modified for
the cloning and expression of antibody fragments. For this
purpose, the terminator T4 [46] and a sequence encoding
the 6xHis-tag were introduced using the two hybridised
oligonucleotide primer EJoligoHisTermf and EJoligoHis-
Termr with the restriction sites SphI and AgeI. A residual
part of the E. coli tetracycline resistence gene was deleted
by digestion with AflII and religation. Furthermore, the
signal peptide splipA [25] was optimized regarding the
codon usage and a NheI restriction site was introduced for
further cloning steps using the overlapping oligonucle-
otide primer EJopSplipAf and EJopSplipAr. The signal
peptide gene fragment was cloned into the BglII/BsrGI
restriction site, resulting in the vector pEJBmopSplipA.
These cloning steps were performed in E. coli DH5α (Inv-
itrogen, Karlsruhe, Germany). The DNA encoding the
D1.3 scFv was amplified from the plasmid pHAL1-
D1.3scFv, an scFv variant of pHAL1-D1.3 [32], using the
oligonucleotide primer EJD1.3NheIf and EJD1.3r and
cloned into the NheI/NotI site to yield pEJBmD1.3scFv.
This cloning step was performed in E. coli DH10B contain-
ing the plasmid pMMEc4, encoding the xylose repressor
protein to ensure the repression of the Xylose promoter
during the cloning step in E. coli. The plasmid pMMEc4
was derived from pBAD33 (ATCC 87402) by cloning the
amplified xylose repressor gene using the oligonucleotide
primer XylRfor and XylRrev from B. megaterium DSM319
into the SacI/SphI site. Transformation of E. coli DH10B
[pMMEc4] with pEJBmD1.3scFv was performed as out-
lined before [45]. All affected regions of the constructs
were confirmed by DNA sequencing using an ABI Prism
310 sequencer. All oligonucleotide primer sequences are
given in Table 1.
Transformation of B. megaterium
Transformations of non-sporulating B. megaterium strain
MS941 [47] were performed as described by Barg et al.
[48].
Production and export of scFvs using B. megaterium
The D1.3 scFv was produced in shaking flasks. 100 mL
medium + 10 μg/mL tetracyline were inoculated with 1
mL overnight culture at 37°C and 250 rpm. The media
used were A5 pH 6.8 (30 g/L glucose, 2 g/L (NH4)2SO4,
0.3 g/L MgSO4, 0.5 g/L yeast extract, 3.5 g/L KH2PO4, 7.3
g/L NaHPO4 × 2H2O, 40 mg/L MnCl × 2H2O, 53 mg/L
CaCl2  × 2H2O, 2.5 mg/L FeSO4  × 7H2O, 2.5 mg/L
(NH4)6Mo7O24 × H2O, 2.5 mg/L CoCl2 × 6H2O), M9, LB,
2xTY and TB [45]. The induction was started by adding 0.5
% xylose at O.D.600 nm = 0.3 – 0.4. The culture was shakenMicrobial Cell Factories 2007, 6:2 http://www.microbialcellfactories.com/content/6/1/2
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at 250 rpm and temperatures from 23°C to 45°C for up
to 48 h. The supernatant was directly used for ELISA. For
SDS-PAGE analysis and protein purification, the proteins
of the supernatant were precipitated using 440 g/L ammo-
nium sulfate.
Production of scFvs in E. coli
The D1.3 scFv was produced in shaking flasks according to
Dübel et al. [37] using the vector pOPE101 [49] and the
E. coli strain XL1-Blue MRF' (Stratagene, Amsterdam,
Netherland). Briefly, 300 mL 2 × TY + 100 mM glucose +
100 μg/mL ampicillin were inoculated with an overnight
culture yield to O.D.600 nm = 0.1 and cultured at 37°C and
250 rpm. The scFv production was induced by adjusting
to 50 μM IPTG at O.D.600 nm = 0.5 and shaking for 3 h at
30°C. Bacteria were harvested by 10 min at 4400 × g and
4°C. The supernatant was used for ammonium sulfate
precipitation (see below). Bacteria pellets were resus-
pended in 30 mL ice cold PE buffer, pH 8 (20 % sucrose,
50 mM Tris, 1 mM EDTA) and incubated for 20 min on
ice, interrupted by short vortexing every 2 min. Subse-
quently the bacteria were pelleted for 30 min at 30,000 ×
g and 4°C. The supernatant (periplasmic fraction) was
stored at -20°C. The remaining supernatant from the first
bacteria centrifugation was precipated using 132 g/300
mL ammonium sulfate, stirred 1 h at 4°C and centrifuged
for 20 min at 7700 × g and 4°C. The protein pellet was
dissolved in 10 mL PBS. The periplasmic fraction and the
precipitated supernatant were combined and dialysed
over night against PBS at 4°C.
Immobilized metal affinity chromatography (IMAC) 
purification of antibody fragments
Antibody fragments were purified from E. coli or B. mega-
terium derived material by affinity chromatography using
IMAC. Chromatography using 1 mL Chelating Sepharose
Fast Flow (Amersham Biosciences, Freiburg, Germany)
was performed according to the manufacturers' instruc-
tion. The protein solution was adjusted to 10 mM imida-
zol containing buffer (20 mM Na2HPO4, 500 mM NaCl,
10 mM imidazol) for loading The column was washed
one time with 10 mM imidazol, twice with 50 mM imida-
zol buffer and once with PBS. Two times 50 mM
NaH2PO4, 300 mM NaCl and 250 mM imidazol and fin-
aly with phosphate buffered saline (PBS) [45], pH 7.4,
100 mM EDTA were used for the elution.
Antigen binding ELISA
Maxisorb MTPs (Nunc, Wiesbaden, Germany) were
coated with 1 μg hen egg white lysozyme or 1 μg BSA in
100 μL PBS per well overnight at 4°C. Coated wells were
washed three times with PBST (PBS + 0,1% (v/v) Tween
20) and blocked with 2% (w/v) skim milk powder in
PBST for 1.5 h at RT, followed by three times washing with
PBST. Soluble antibody fragments were diluted in 100 μL
blocking solution and incubated for 1.5 h, followed by
three times washing with PBST. Soluble antibody frag-
ments were detected with mAb mouse anti-penta His-tag
(1:10000) (Qiagen, Hilden, Germany) and polyclonal
goat anti-mouse IgG conjugated with horse radish perox-
idase (HRP) (Fab specific) (1:10000) (Sigma,
Taufkirchen, Germany) and visualised with 100 μL TMB
(3,3',5,5 '-tetramethylbenzidine) substrate. The staining
reaction was stopped by adding 100 μL 1 N sulphuric
acid. The absorbances at 450 nm and scattered light at 620
nm were measured using a microtitre plate reader SUN-
RISE (Tecan, Crailsheim, Germany). The absorbance at
620 nm was subtracted.
SDS-PAGE and Immunoblot
Soluble antibody fragments were separated by SDS-PAGE
[50] and blotted onto polyvinyl fluoride (PVDF) mem-
brane (millipore, Schwalbach, Germany). The membrane
was blocked with 3% (w/v) skim milk powder in PBS for
1 h at RT. For the detection of soluble antibody fragments
the mAb mouse anti-penta His-tag (1:2000) (Qiagen,
Hilden, Germany) was used as first antibody and goat
anti-mouse IgG (Fab specific) conjugated with alkaline
phosphatase (AP) (Sigma, Taufkirchen, Germany)
(1:5000) was used as second antibody. The visualisation
was done by NBT/BCIP.
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